Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVRONASDAQ:FENCNASDAQ:KODNASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsFENCFennec Pharmaceuticals$7.93-4.7%$6.67$3.96▼$8.72$218.87M0.495,726 shs65,055 shsKODKodiak Sciences$3.88+5.4%$3.59$1.92▼$11.60$204.72M2.27347,984 shs277,777 shsTVGNTevogen Bio$1.24-2.4%$1.14$0.26▼$3.09$228.03M-0.695.05 million shs556,484 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVROAVROBIO0.00%0.00%0.00%0.00%-92.22%FENCFennec Pharmaceuticals-4.69%-5.93%+25.28%+21.81%+15.43%KODKodiak Sciences+5.43%-8.06%-1.52%+6.59%+39.07%TVGNTevogen Bio-2.36%-13.29%+12.73%+5.98%+42.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVROAVROBION/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.4903 of 5 stars3.62.00.00.02.23.30.0KODKodiak Sciences4.2958 of 5 stars3.04.00.04.61.73.30.6TVGNTevogen Bio4.0954 of 5 stars3.54.00.00.03.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVROAVROBIO 0.00N/AN/AN/AFENCFennec Pharmaceuticals 3.25Buy$13.0063.93% UpsideKODKodiak Sciences 2.00Hold$9.00131.96% UpsideTVGNTevogen Bio 3.00Buy$7.10472.58% UpsideCurrent Analyst Ratings BreakdownLatest AVRO, TVGN, FENC, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/27/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/20/2025FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/14/2025FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.005/12/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/29/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/21/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVROAVROBION/AN/AN/AN/A$2.13 per shareN/AFENCFennec Pharmaceuticals$30.91M7.08N/AN/A($0.43) per share-18.44KODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($1.10) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVROAVROBIO$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/AFENCFennec Pharmaceuticals-$16.05M-$0.51N/AN/AN/A-2.30%-53.38%-2.08%8/12/2025 (Estimated)KODKodiak Sciences-$260.49M-$3.63N/AN/AN/AN/A-84.52%-45.40%8/13/2025 (Estimated)TVGNTevogen Bio-$70KN/A0.00∞N/AN/A-396.07%749.97%8/4/2025 (Estimated)Latest AVRO, TVGN, FENC, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/13/2025Q1 2025FENCFennec Pharmaceuticals-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVROAVROBION/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVROAVROBION/A26.1726.17FENCFennec PharmaceuticalsN/A7.807.64KODKodiak SciencesN/A8.428.42TVGNTevogen BioN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVROAVROBIO62.63%FENCFennec Pharmaceuticals55.51%KODKodiak Sciences89.06%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipAVROAVROBIO9.20%FENCFennec Pharmaceuticals11.76%KODKodiak Sciences45.30%TVGNTevogen Bio73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVROAVROBIO1344.89 million40.76 millionOptionableFENCFennec PharmaceuticalsN/A27.60 million24.54 millionOptionableKODKodiak Sciences9052.76 million28.79 millionOptionableTVGNTevogen Bio3183.89 million75.97 millionN/AAVRO, TVGN, FENC, and KOD HeadlinesRecent News About These CompaniesTevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars InitiativesJune 12 at 9:59 PM | nasdaq.comTevogen Bio's (TVGN) Buy Rating Reaffirmed at D. Boral CapitalJune 11 at 2:37 AM | americanbankingnews.comTevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from MicrosoftJune 10, 2025 | nasdaq.comTevogen Bio doubles Warren HQ footprint for AI expansionJune 10, 2025 | njbiz.comAmbitious Tevogen makes expansion announcementJune 10, 2025 | thepharmaletter.comTevogen Bio (NASDAQ:TVGN) Given "Buy" Rating at D. Boral CapitalJune 10, 2025 | marketbeat.comRyan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) StockJune 10, 2025 | insidertrades.comInsider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) CEO Sells 1,438,206 Shares of StockJune 9, 2025 | marketbeat.comTevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars InitiativesJune 9, 2025 | globenewswire.comtevogen bio expands office lease in new jersey with key amendmentJune 5, 2025 | investing.comTevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijzigingJune 4, 2025 | nl.investing.comTevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapieJune 1, 2025 | nl.investing.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short InterestJune 1, 2025 | marketbeat.comTevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI TechnologiesMay 30, 2025 | quiverquant.comTevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks PartnershipsMay 30, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral CapitalMay 28, 2025 | marketbeat.comTevogen Peports Plans to Increase the Target Population for TVGN 489May 26, 2025 | msn.comTevogen expands target for COVID treatment to seniorsMay 24, 2025 | investing.comTevogen Bio Inc: Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to ...May 24, 2025 | finanznachrichten.deTevogen breidt doelgroep voor COVID-behandeling uit naar 65-plussersMay 23, 2025 | nl.investing.comTevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to FollowMay 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVRO, TVGN, FENC, and KOD Company DescriptionsAVROBIO NASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Fennec Pharmaceuticals NASDAQ:FENC$7.93 -0.39 (-4.69%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.92 -0.01 (-0.19%) As of 06/13/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Kodiak Sciences NASDAQ:KOD$3.88 +0.20 (+5.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.03 +0.15 (+3.87%) As of 06/13/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Tevogen Bio NASDAQ:TVGN$1.24 -0.03 (-2.36%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.24 0.00 (-0.40%) As of 06/13/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
